Xenon Pharmaceuticals (XENE) Operating Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has reported Operating Expenses for 14 consecutive years, with $112.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 28555.1% year-over-year to $112.3 million; the TTM figure through Mar 2026 stood at -$64.8 million (up 68.45% YoY), while the FY2025 annual figure was -$332000.0, up 89.02% from the prior year.
• Operating Expenses climbed to $112.3 million in Q1 2026 per XENE's latest filing, from -$271.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $112.3 million in Q1 2026 and bottomed at -$271.1 million in Q4 2025.
• Historically, Operating Expenses has averaged $8.3 million across 5 years, with a median of $38.3 million in 2022.
• Annual changes were most pronounced in 2025 — Operating Expenses tumbled 577.55% — and 2026, when it jumped 28555.1%.
• Xenon Pharmaceuticals' Operating Expenses stood at $43.3 million in 2022, then rose by 23.92% to $53.7 million in 2023, then plunged by 481.5% to -$204.8 million in 2024, then slumped by 32.36% to -$271.1 million in 2025, then jumped by 141.43% to $112.3 million in 2026.
• Business Quant data shows XENE's Operating Expenses at $112.3 million in Q1 2026, -$271.1 million in Q4 2025, and $96.3 million in Q3 2025.